★ Analysts see FY2027 revenue reaching $188M — +1574% growth in a single year.
What Moves the Stock
01Clinical trial data readouts for zidesamtinib (NVL-520) in ROS1+ NSCLC - objective response rates (ORR), duration of response (DOR), and intracranial activity
02NVL-655 Phase 1/2 data in ALK+ NSCLC, particularly activity against lorlatinib-resistant mutations and CNS metastases
03FDA regulatory interactions - IND clearances for new programs, breakthrough therapy designations, or accelerated approval pathways
04Strategic partnerships or licensing deals with large pharma for ex-US rights or combination therapy development
05Competitive developments from Pfizer, Roche, Takeda, or emerging TKI developers affecting market positioning
06No current revenue - pre-commercial stage
07Future potential: Product sales from zidesamtinib (NVL-520) for ROS1+ NSCLC upon approval
08Future potential: Product sales from NVL-655 for ALK+ NSCLC and licensing/partnership revenues
growth - Attracts specialized biotech investors, healthcare-focused hedge funds, and venture capital crossover funds seeking high-risk…
Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (first revenues likely 2028+).
Watch on earnings: Zidesamtinib (NVL-520) Phase 2 objective response rate (ORR) and intracranial response rate versus 70%+ target, NVL-655 activity against ALK G1202R and compound mutations resistant to lorlatinib, Quarterly cash burn rate and remaining runway to key data readouts.
One Sentence Summary:
Nuvalent: the story is balanced — clinical trial data readouts for zidesamtinib (nvl-520) in ros1+ nsclc - objective response rates (orr), duration of response (dor).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
